ArticlePediatric research2026
The association analysis between Glucose-6-Phosphate dehydrogenase deficiency and susceptibility to common diseases in children.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study investigates the relationship between G6PD deficiency and susceptibility to common pediatric diseases.
methodsA retrospective analysis was conducted on hospitalized children who underwent G6PD screening at the Guangzhou Women and Children's Medical Center from January 2019 to March 2024.
resultsAmong 36,619 children, 20,662 were male. The prevalence of G6PD deficiency in males was significantly higher in conditions such as nephritis (OR 2.43,95%CI 1.45-4.21), allergic purpura (OR 2.24, 95%CI 1.24-4.09), patent ductus arteriosus (OR 2.04, 95%CI 1.32-3.33), atrial septal defect (OR 2.14, 95%CI 1.41-3.45), ventricular septal defect (OR 1.73, 95%CI 1.12-2.80), and type 1 diabetes (OR 2.04, 95%CI 1.16-3.66). Among 15,957 female patients, the prevalence of G6PD deficiency was significantly elevated in systemic lupus erythematosus (SLE) (OR 1.87, 95%CI 1.27-2.70), juvenile arthritis (OR 1.79, 95%CI 1.16-2.68), nephritis (OR 1.72, 95%CI 1.16-2.49), patent ductus arteriosus (OR 1.27, 95%CI 1.00-1.61), atrial septal defect (OR 1.33, 95%CI 1.10-1.61), and ventricular septal defect (OR 1.55, 95%CI 1.26-1.91).
conclusionG6PD deficiency may increase the risk of autoimmune diseases, congenital heart defects, and type 1 diabetes in children. Further studies are required to elucidate its role in pediatric disease susceptibility and inform clinical management. IMPACT: 1. This study found that G6PD deficiency is significantly associated with increased susceptibility to several common pediatric diseases, including autoimmune diseases, congenital heart defects, and type 1 diabetes. Notably, in both male and female patients, G6PD deficiency was significantly linked to specific conditions, such as SLE, juvenile arthritis, and congenital heart disease. 2. Our findings indicate that G6PD deficiency is not merely an enzymatic defect but may also impact the immune and cardiovascular systems. Specifically, an increased incidence of congenital heart disease has been observed in children with G6PD deficiency for the first time.
Indexed as
Identifiers
40425847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.